This simple ABC (Atrial brillation Better Care) approach would simplify an integrated approach to AF management in a holistic manner (Fig 1).2 This guideline focuses on stroke prevention and begins with a brief discussion of the methods used to develop these guidelines and the recommendations for antithrombotic therapy in patients with AF. Next, we provide our treatment recommendations, divided into the following sections:  Stroke and bleeding risk assessment  Antithrombotic therapy in patients with AF in general (includes patients with permanent, persistent, or paroxysmal AF)  Antithrombotic therapy in patients with AF in special situations: B Managing bleeding B Antithrombotic therapy for patients with AF undergoing cardioversion B Acute coronary syndrome (ACS) and stenting B Stable coronary artery disease B Rhythm control and electrophysiological procedures B Acute ischemic stroke, intracranial hemorrhage (ICH), embolic stroke of undetermined source (ESUS), carotid disease B Atrial high-rate episodes (AHREs) on devices B Chronic atrial utter B Pregnancy B Chronic kidney disease (CKD) B Valvular heart disease The article ends with a discussion of practical and patient-centered issues as well as suggestions for future research. Methods Expert Panel Composition The chair of the panel (G.Y.H.L.) was appointed and subsequently reviewed and approved by CHEST s Professional Standards Committee. Panelists were nominated by the chair based on their expertise relative to potential guideline questions. Con icts of Interest All panel nominees were reviewed for their potential con icts of interest (COIs) by CHEST s Professional Standards Committee. After review, nominees who were found to have no substantial COIs were approved, whereas nominees with potential intellectual and nancial COIs that were manageable were approved with management. Panelists approved with management were prohibited from participating in discussions or voting on recommendations in which they had substantial COIs. 